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ABSTRACT 
Objective: The present study aims to utilize the nanotechnology technique to formulate the Cinnarizine (CNZ) in the form of solid self-nano 
emulsifying system to enhance the dissolution and hence the bioavailability. 
Methods: Screening study for solubility of CNZ in different vehicles was carried out. The selected system was optimized for saturated solubility, 
globule size, zeta potential, polydispersity index (PDI) and self-emulsification time. The solidified nanoemulsion was prepared using; Aeroperl 300, 
Aerosil 200, hydrophilic nanosilica and Neusilin US2 as porous carrier materials. The compressed CNZ tablets were evaluated regarding their 
physicochemical characteristics, in-vitro release, and bioavailability study.  
Results: Self nano-emulsifying system composed of Labrafil (oil), tween 80 (surfactant), and transcutol (cosurfactant) was successfully developed 
with a droplet size range of 11.37-92.58 nm. The in-vitro release results revealed that the developed formulation improved the release of CNZ and 
enhanced the bioavailability in the rabbits (190%) more than the commercial product (Stugeron® tablets).  
Conclusion: Solid self-nano-emulsifying system of CNZ was successfully developed by different ratios of Labrafil (oil), tween 80 (surfactant), 
transcutol (cosurfactant) and solidified by the adsorption on hydrophilic nano silica and the optimized formula could be expected to increase and 
improve the bioavailability of CNZ. 
Keywords: Pseudo-ternary phase diagram, Self-nanoemulsion, Porous carriers, Bioavailability study. 
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INTRODUCTION 
Microemulsions are clear thermodynamically stable, composed of an 
isotropic mixture of natural or synthetic oil with lipophilic or hydrophilic 
surfactant and co-solvents [1-3]. They can act as drug delivery vehicles 
by incorporating a wide range of drug molecules [4, 5]. Self-nano 
emulsifying drug delivery systems undergo emulsification by gentle 
agitation in the presence of gastric fluid to form oil in water emulsion 
with droplet size ranging between 10-200 nm are called as self-nano 
emulsifying drug delivery system, whereas droplet size ranging between 
100 and 200 nm are known as self-micro emulsifying drug delivery 
system [6,7]. Self-nano emulsifying drug delivery system have many 
advantages include; increased drug loading, enhancing of drug 
penetration through the biological membranes so increased the 
bioavailability, the ease of preparation due to the spontaneous 
formation, thermodynamic stability, transparent and elegant appearance 
[8,9]. There are few limitations associated with self-nanoemulsion (SNE) 
when presented in capsules, including the precipitation of the drug 
during manufacture and storage and the incompatibility of the 
formulation components with the capsule shell [10]. To overcome these 
problems, the concept of solid SNE was developed. Various techniques, 
such as freeze drying, spray drying, and adsorption on porous carriers, 
can be employed to convert liquid SNE into solid depending [11, 12]. 
Cinnarizine (CNZ) is a piperazine derivative with high affinity to H1 
receptors that can be used in allergic conditions. However it is practically 
insoluble in water (aqueous solubility less than 1 μg/ml exhibit low oral 
bioavailability, which due to its poor and pH-dependent dissolution of 
the drug rate [13-15]. The objective of this work was to utilize 
nanotechnology to formulate CNZ into SNE tablets that increase drug 
dissolution and in turn, increasing the bioavailability of the drug. 
MATERIALS AND METHODS 
Materials  
Cinnarizine was kindly gifted by Arab drug company (ADCO), Egypt. 
Tween80 (Polyoxyethylene sorbitan monooleate, HLB=15), 
Cremophore RH 40 (Polyoxyethylene 40 hydrogenated castor oil, 
HLB 14–16) and Aeroperl 300 (granulated silicon dioxide) were 
kindly gifted from Degussa, Germany. Avicel® PH 102 
(Microcrystalline cellulose), Ac-Di-Sol® (crosscarmellose sodium) 
and Propylene glycol were purchased from Sigma-Aldrich (Saint 
Louis, MO, USA). Labrafil M 1944 CS (Oleoyl macrogol-glycerides) 
and Labrafac lipophile WL 1349 (Medium chain triglycerides) were 
kindly gifted by Gattefosse, France. Soyabean oil and oleic acid 
(Octadecenoic acid) were purchased from, Lab Chemicals Trading 
Co., Egypt. Hydrophilic nano silica and Neusilin US2 (Magnesium 
Aluminometasilicate) were purchased from NanoTech Co., Egypt. 
Transcutol HP was a gift from Gattefosse® France.  
Methods 
Solubility studies 
An excess amount of CNZ was added to 2 ml of various oils, 
surfactants, and cosurfactants, and mixed by a vortex mixer. The 
mixture was kept at 25 °C for 72 h till equilibrium. The sample was 
centrifuged at 1000 rpm for 10 min and filtered. The filtrate diluted 
with methanol and then the amount of CNZ was determined by UV 
spectroscopy at λmax 254. 
Construction of pseudo-ternary phase diagrams 
The selected oil (Labrafil), surfactant (tween 80) and co-surfactant 
(transcutal) were used to prepare the self-nanoemulsion 
preconcentrate system. 36 possible ratios were used to construct 
the phase diagram. 0.1 ml of each of the prepared self-
nanoemulsion preconcentrates were mixed using a vortex mixer 
then diluted with 100 ml deionized water, and magnetically 
stirred at 500 rpm for 2 min at room temperature. The diluted 
products were inspected against a dark background and were 
discriminated as clear, turbid or biphasic [16]. Only the clear 
emulsions are considered as nanoemulsion with droplet size 200 
nm or less [17].  
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Optimization of the selected system  
Saturated solubility study  
Excess amount of the drug was added into 2 ml of each of the clear 
ratios in the selected system (table 1) and mixed by a vortex mixer 
and moved to thermodynamically water bath shaker for 72 h at 
(25±0.5 °C) then centrifuged at 5000 rpm for 20 min. The 
supernatant was diluted with phosphate buffer pH 6.8 using 
magnetic stirrer at 500 rpm for 2 min [18]. The amount of dissolved 
drug was determined using UV spectroscopy at λmax 254 nm. 
  
Table 1: The composition of the different self-nanoemulsion pre-concentrates systems 
System Labrafil M 1944 CS Tween 80 Transcutol 
System I 20% 50% 30% 
System II 20% 60% 20% 
System III 20% 70% 10% 
System IV 10% 50% 40% 
System V 10% 60% 30% 
System VI 10% 70% 20% 
System VII 10% 80% 10% 
*In each system 0.1 ml pre-concentrate was diluted with 100 ml deionized water. 
 
Robustness to dilution of SNE 
Robustness to dilution was studied by diluting the prepared SNE (2 
ml) with (200 ml) water. The diluted SNE were stored for 12 h and 
observed visually for clarity, signs of phase separation, and the 
quality of emulsion produced [19]. 
Particles size analysis and zeta potential measurement of SNE 
The prepared SNE system were diluted with water, and the average 
particles size were determined using dynamic light scattering by 
Malvern Zetasizer (Zetasizer 3000, Malvern Ltd., UK) [20]. Zeta 
potential was determined using a photon correlation spectrometer 
based on the laser light scattering phenomenon. Samples were 
diluted 200 times with deionized water prior to measurement [21]. 
Self-emulsification time and percentage of transmittance 
Determination of self-emulsification time was carried out by dilution 
of 0.5 ml of SNE in a glass beaker with 100 ml distilled water then 
mixed gently by using magnetic stirrer at room temperature with a 
rotation speed of 100 rpm. The time is taken by the SNE to form 
homogenous nano emulsion was measured, and the percentage of 
transmittance was measured at 638.2 nm, using distilled water as 
the blank by UV spectrophotometer [22]. 
Development of CNZ liquid-SNE 
CNZ (25 mg) was added to the optimized SNE (0.1 ml) in a glass vial 
then mixed by Sonicator for 20 min till drug was dissolved. The 
mixture was stored at room temperature until further investigations.  
Surface morphology determination of the optimized CNZ-SNE 
The high-resolution transmission electron microscope (TEM, 
JEM-1400, Japan) was used to evaluate the morphology of the 
liquid CNZ-SNE. The samples were diluted up to 100 times with 
deionized water to form nano emulsion. In the TEM technique, a 
drop of the formed nano emulsion was loaded on a carbon-
coated copper grid. The excess was removed immediately using 
filter paper. 2% w/v aqueous solution of phosphotungstic acid 
(staining agent) was directly added to the grid and left for 45 
seconds. Then, they were allowed to dry for 1 hour. After drying, 
the grid was directly investigated and photographed using (TEM, 
JEM-1400, Japan). 
Development of CNZ solid-self nano emulsifying system 
The optimized liquid SNE formulation was transformed into solid 
granules through using different inert porous carriers (Aeroperl 
300, Aerosil 200, hydrophilic nano silica and Neusilin US2) as 
adsorbing agents due to their oil adsorption property [23]. The 
porous carriers were added to a fixed volume of the liquid SNE (0.1 
ml) containing (25 mg CNZ) in increments amounts with shaking 
until the formation of free fluid powder. The final weight of the 
formed free fluid granules were determined (table 2). 
Preparation of CNZ self nano emulsifying tablets 
The resulting granules were mixed with the binder (Avicel PH101) 
and 3% w/w of disintegrant (Ac-Di-Sol) was added to the mixture 
and mixed for 10 min and complete the final weight with lactose 
(table 2). Prepared powders were compressed into an oval, curve 
faced tablets of 500 mg using tablet press machine (Rimek Mini 
Press, Model RSB-4, Kanavati Engineering). 
Optimization of the prepared CNZ self-nano emulsifying tablets 
Physicochemical properties of the prepared CNZ-SNE tablets 
The weight uniformity was determined for the tablets, and the 
friability was also determined using a friabilator at 25 rpm for 4 min. 
The friability is expressed in percent of weight loss. The uniformity of 
CNZ content was determined by crushing tablets from each system 
and determining the content by dilution with methanol and measuring 
spectrophotometry for their CNZ content. The mean hardness was 
measured using Erweka hardness tester and expressed in kg. Finally, 
the disintegration time of tablets was determined in minutes using the 
disintegration test apparatus (Pharma Test, Type PTZ3). 
In vitro release of CNZ from the prepared CNZ-SNE tablets 
The dissolution of CNZ from the prepared tablets was performed in 900 
ml of standard phosphate buffer (pH 6.8) at 37±0.5 °C using dissolution 
tester (Erweka, model, Germany), Apparatus II (rotating paddle the USP 
Dissolution test), at a rotation of 75 rpm. 10 ml from the dissolution 
medium was withdrawn at 5, 10, 15, 20, 30, 45 and 60 min. Samples 
were filtered through 0.45-μm filter (PVDF membrane, Millipore Corp., 
USA) and analyzed spectrophotometry (Shimadzu 1800, Japan) at 254 
nm. The drug release from the formulation was measured and compared 
with the conventional marketed CNZ tablet (Stugeron®). 
 
Table 2: Preparation of self-nano emulsifying tablets 
Tablet components G1 G2 G3 G4 
Aeroperl 300-SNE 290 mg ----------------  ---------------- 
Aerosil 200-SNE ---------------- 340 mg  ---------------- 
Hydrophilic nanosilica–SNE ---------------- ---------------- 230 mg ---------------- 
Neusiln US2-SNE ---------------- ---------------- ---------------- 256 mg 
Tablet components F1 F2 F3 F4 
20% Avicel PH101 (Binder) 100 mg 100 mg 100 mg 100 mg 
3% Ac-di–sol (disintegrant) 15 mg 15 mg 15 mg 15 mg 
* 25 mg of the drug was added to each formulation, *The weight of each prepared tablet was completed to 500 mg by addition of lactose as filler 
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Bioavailability 
Study design  
The in-vivo study was conducted according to the institutional guidelines 
of the Animal Ethics Committee of the faculty of pharmacy Beni-suief 
University. The study was carried out using 12 healthy albino rabbits 
(New Zealand) weighing 2.5–3.0 kg to compare the CNZ pharmaco-
kinetics (treatment A) of the optimized SNE-tablet to the commercially 
tablet Stugeron® (treatment B). The animals were fasted for 24 h before 
the administration of dose (allow to drink water) and were divided to 
two equal groups. The first group was administered the reference 
(Stugeron tablet) at a dose of 25 mg/kg while the second group was 
administered CNZ-SNE tablet at a dose of 25 mg/kg [24]. 
Sample collection 
Blood samples (2 ml) were collected into heparinized tubes at 0.25, 0.5, 
0.75, 1, 1.5, 2, 3, 4, 6, 10, 12 and 24 h after the administration. The blood 
samples were centrifuged at 4,000 rpm and the separated plasma 
samples were stored) at −20 °C in a deep freezer, until further analysis. 
Extraction procedure 
0.5 ml from plasma was added to 0.5 ml (2 µg/ml) of internal 
standard (Meclozine HCl) and acidified by addition of 0.2 ml of HCl 
(1N), then 5 ml of chloroform was added and centrifuged for about 
10 min at 2,000 rpm. The chloroformic layer was separated and 
evaporated till dryness. Finally, the residual was reconstituted with 
500 µl of the mobile phase, vortex then filtered through filter disk in 
ependorff tube, then analyzed by HPLC. 
Chromatographic conditions 
A reported validated and sensitive HPLC (Bond pack C18 column) of 
modified Hasan Extraction et al., method was used [25]. The mobile 
phase consists of acetonitrile: water (6:4) in which 1.5 gram of 
sodium heptano-sulphonate was dissolved per liter. The pH of the 
mobile phase was adjusted to 3.5 with 0.1N sulphoric acid. After 
filtration through a membrane filter, the mobile phase was degassed 
and pumped at flow rate 1 ml/min. The UV detector was adjusted at 
254 nm and the element peaks were investigated using peak height 
ratio, all assays were performed at ambient condition. 
Determination of pharmacokinetic parameters  
The tmax, Cmax, AUC0-∞, t1/2 and MRT (mean resident time) were 
calculated using the plasma concentration-time curve in the 
WinNonlin Nonlinear compartment Program. One-way analysis of 
variance was employed to assess the significance of the difference. 
RESULTS AND DISCUSSION 
Solubility studies 
Screening of the solubility of the drug in the different vehicle was 
carried out to avoid the precipitation of the drug upon dilution in the 
in-vivo. The solubility of CNZ in various oils, surfactants and 
cosurfactant, was identified (fig. 1). The solubilisation of CNZ was 
highest with Labrafil oil (74.32±3.76 mg/ml) compared with other 
studied oils, for surfactant; tween 80 showed a superior solubility 
(70.36±3.81 mg/ml) and finally, transcutol had the highest solubility 
among the co-surfactant studied (110.32±4.78 mg/ml). 
 
 
Fig. 1: Solubility studies of CNZ in each oil, surfactant, and co-
surfactant 
 Construction of pseudo-ternary phase diagram 
A ternary phase diagram was constructed using Labrafil as oil, 
Tween 80 as surfactant and Transcutol as co-surfactant to 
determine the optimum ratio of oil: surfactant: co-surfactant 
mixtures. The clear points in (fig. 2) are those forming clear 
transparent emulsions after dilution with distilled water. 
 
 
Fig. 2: Pseudo-ternary phase diagrams for (SNE) pre-
concentrate systems consists of Labrafil (oil), tween 80 
(surfactant), and transcutol (cosurfactant) showing clear 
combinations after dilution with distilled water 
 
Optimization of the selected systems 
Robustness to dilution 
The dilution capacity of each system was determined to study the 
effect of dilution on the stability of the nano emulsion when 
subjected to dilution by the GIT fluids; this may result in a gradual 
desorption of surfactant located at the droplet interface. This 
process depends upon the requirement of the surfactant for 
maintaining the aqueous phase concentration equivalent to its 
critical micelle concentration [26]. The seven selected SNE systems 
(table 1) are those, which, upon dilution with distilled water 
produced a clear nano emulsion when observed visually. 
Globule size and poly dispersity index (PDI) 
The droplet size of the emulsion is a critical factor in self-
emulsification performance because it determines the rate and 
extent of drug release and consequently its absorption [27]. All the 
prepared SNE had droplets size in the range of 11.37-92.58 nm 
(table 3). There is a relationship between the droplet size and the 
concentration of the surfactant being used. It has been reported that 
droplets with smaller mean droplet size could be obtained upon 
increasing the surfactant concentration [27]. Similar in this study, it 
was noted that upon increasing the surfactant ratio the obtained 
droplets were smaller in size. This could be explained by the fact 
that the surfactant stabilizes the O/W interface, and its 
concentration increased at the interface upon decreasing the oily 
content. That attributed to a decrease in the emulsion particle size 
thus a more clear-appearing emulsion was produced [28]. However, 
an increase in co-surfactant concentration was accompanied by an 
increase in droplet size. This could be attributed to the interfacial 
disruption elicited by enhanced water penetration into the oily 
droplets mediated by the increased co-surfactant concentration and 
leading to the ejection of oil droplets into the aqueous phase [29]. 
PDI is the ratio between the standard deviation and the mean 
globule size; it indicates the uniformity of the globule size within the 
system. The lower the value of PDI, the higher uniformity of the 
globule size [30]. It was found that PDI range between 0.098-0.353 
indicating a good uniformity of globule size.  
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Zeta potential measurements 
The zeta potential was studied to indicate the stability and the 
degree of repulsion between the individual particles. The presence 
of a small negative charge of zeta potential (table 3) has no effect on 
the stability of nano-emulsion. 
Development of CNZ-liquid SNE 
From the previous physicochemical character, System VI containing 
10% Labrafil oil, 70% tween 80 and 20% transcutal was selected for 
the further characterizations. 
Surface morphology determination of the liquid CNZ-SNE 
Transmission electron microscopy for the clear CNZ nano-emulsion 
was study, and the nano-emulsion droplets were observed as 
regular dark droplets surrounded by a thick bright frame well-
identified spherical shaped droplets (fig. 3). The emulsion droplets 
generated have a smooth surface with no crystals of the drug on the 
surface. 
Development and optimization solid CNZ-SNE granules 
The simplest technique to convert liquid SNE to solid SNE granules 
is by adsorption on porous carriers. The different formulation 
composition of CNZ self-nano-emulsifing granules is shown in table 
2. The self-nano-emulsifing granules prepared using porous carriers 
was optimized based on flow properties. All the formulations of 
CNZ-self-nano emulsifing granules showed good flow ability with 
regard to Carr’s index, in the range of 14.77 to 17.93, Hausners’s 
ratio less than 1.2 and angle of repose less than 31º as shown in 
(table 4). 
Evaluation of CNZ self-nano emulsifying tablets 
Table 5 shows the physicochemical properties of the prepared 
tablets, the drug content were found to be in the range of 
(96.04±4.3692-101.56±4.75%) indicating proper mixing and good 
flow ability and uniformity of drug content of the formulation. The 
friability values were in accepted range according to the criteria of 
the USP (less than1 %). The recorded hardness values were 3.97±0.3 
kg to 4.98±0.21 kg. The disintegration time were less than two 
minutes reflecting the efficiency of Ac-di–sol (3%) as a disintegrant.
 
Table 3: Optimization of the selected self-nano emulsifying systems 
Emulsification time (sec) Zeta potential  (MV) PDI* Z-Average (nm) Solubility System 
61 −9.73±0.52 0.353 92.58±4.56 52.58±4.56 System I 
74 −10.55±0.57 0.286 71.47±2.34 63.13±5.340 System II 
42 −12.43±0.49 0.227 41.72±3.13 71.72±4.392 System III 
66 −13.76±0.36 0.127 18.59±0.1 98.59±3.803 System IV 
42 −9.93±0.12 0.239 13.89±0.07 84.89±5.373 System V 
23 −9.78±0.33 0.0973 11.03±0.05 114.81±6.193 System VI 
28 −9.13±0.22 0.0941 14.37±0.05 101. 27±6.051 System VII 
*PDI: Poly dispersity Index, Data expressed as mean±standard deviation 
 
  
Fig. 3: Transmission electron microscopy of the optimized CNZ liquid-SNE with different magnification 
 
Table 4: Micrometrics properties of the prepared granules 
Formula F1 F2 F3 F4 
Carr’s index 16.40 17.93 14.77 16.33 
Hausner’s ratio 1.196 1.218 1.173 1.195 
Angle of repose±S. D* 28.42±0.48 30.32±0.49 27.36±0.28 29.28±1.03 
*Standard deviation 
 
Table 5: Physicochemical Properties of the prepared tablets 
Formula F1 F2 F3 F4 
Drug content (%)±S. D* 96.04±4.36 101.56±4.75 98.25±3.92 99.69±2.95 
Hardness (kg)±S. D* 4.74±0.45 3.97±0.33 4.98±0.21 4.82±0.51 
% Friability 0.78 0.83 0.58 0.68 
Disintegration time (Seconds)±SD* 110.45±6.73 98.11±7.23 63.38±4.12 86.450±7.45 
*Standard deviation, *All the physicochemical properties were in the accepted range. 
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Fig. 4: Dissolution of CNZ from different prepared SNE-tablets 
formulations in comparison with the market tablets (Stugeron®) 
 
Dissolution study 
Dissolution studies were performed for the prepared SNE tablets 
formulations, and the conventional market tablets (Stugeron®). The 
release percentage of CNZ from the SNE tablets was significantly 
higher than that of the conventional tablet (fig. 4). The amounts of 
drug released after 5 min were 66.74, 58.34, 71.35 and 68.34% of 
the labeled amounts for F1, F2 F3 and F4, respectively. These values 
are significantly higher than that of the market formulations after 
the same period of time (33.45%). It could be suggested that SNE 
tablets increase the release of the drug due to the small droplet size 
(in the nano range), which permits a high drug dissolution in the 
medium, the hydrophilic nano silica containing granules (F3) 
showed the highest dissolution and was selected as the optimized 
SNE formulation for in-vivo study. 
Bioavailability 
The plasma concentration-time profiles for CNZ of the prepared 
tablets (F3) and Stugeron® tablets following oral administration were 
presented in (fig. 5). The pharmacokinetic parameters of CNZ were 
tabulated in (table 6). Results demonstrated that the AUC (0–24) of CNZ 
in SNE tablet increased by about two folds when compared to 
Stugeron® tablets. tmax significant decreased (p<0.05) for SNE tablet 
(1.833±0.246 hour) compared to Stugeron tablets (2.667±0.496 hour).  
The pharmacokinetic study results revealed that SNE tablets of CNZ 
can significantly modify its pharmacokinetic profile and can increase 
its bioavailability to 189.74 % in comparison with the marketed oral 
tablet formulation. This may be attributed to the spontaneous 
formation of the nanoemulsion after oral administration of CNZ-SNE 
tablet. The formed nanoemulsion has droplets with small size that 
provides a large surface area for extensive CNZ absorption. 
 
Table 6: Bioavailability parameters of Cinnarizine SNE tablets 
Pharmacokinetic parameters Formulae 
Marketed formulation SNE tablets (F3) 
Cmax (ng/ml) 106.2567±14.972 195.605±20.177 
tmax (h) 2.667±0.492 1.833±0.246 
AUC(0-24) (ng. h/ml) 1040.838±95.32 591.6329±71.42 
% Relative Bioavailability - 189.74 % 
Kel 0.0795 0.085 
t½ (h) 8.721 8.145 
MRT (h) 10.59±2.12 10.32±1.63 
Data expressed as mean±standard deviation, the mean difference is significant at the 0.05 level. 
 
 
Fig. 5: Plasma concentration profiles of CNZ after oral 
administration of SNE tablets and Stugeron ® tables to albino 
rabbits (mean±SD, n = 6) 
 
CONCLUSION 
The solid self-nano emulsifying formulation of CNZ was successfully 
developed by different ratios of Labrafil (oil), tween 80 (surfactant), 
transcutol (cosurfactant) and solidified by the adsorption on 
different porous carriers. The tablets formulation containing SNE 
adsorbed on hydrophilic nanosilica showed the highest dissolution 
in comparison with the other selected carriers and might be a 
promising approach for enhancing the dissolution and improving 
the oral bioavailability of CNZ. 
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